SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced that it has acquired exclusive rights to develop and commercialize Menadione, a preclinical product candidate for the prevention and treatment of skin rash associated with the use of epidermal growth factor receptor (EGFR) inhibitors in the treatment of certain cancers. The activity of Menadione was discovered in the laboratory of Roman Perez-Soler, M.D., Chief of the Division of Oncology in the Department of Medicine at the Albert Einstein College of Medicine in New York. Dr. Perez-Soler is a leading clinical investigator and Chair of the Department of Oncology at the Montefiore Medical Center. Hana’s rights were obtained pursuant to a license agreement with the Albert Einstein College of Medicine. Pursuant to the license agreement, Hana holds a worldwide, exclusive, royalty-bearing license, with the right to grant sublicenses to pending patent applications relating to topical menadione.
